Please assess the completion status of the following clinical trial:

Trial Title: Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with immediate placement of tissue expanders and have a strong family history or hereditary cancer~2. Age ≥ 18 years~3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception: 2 methods of birth control, prior to study entry ad for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.~4. Ability to understand a written informed consent document, and the willingness to sign it~5. At least 4 weeks post-completion of chemotherapy~6. Adequate organ function within 14 days start of study start:~   1. Absolute neutrophil count (ANC) ≥ 1.5 X 10\^9/L~  2. Hemoglobin (Hgb) ≥9g/dL~  3. Platelets (plt) ≥ 100 x 10\^9/L~  4. Potassium within normal range, or correctable with supplements;~  5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is present;~  6. Serum total bilirubin ≤ 1.5 x ULN~  7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min~Exclusion Criteria:~1. Any significant medical condition, laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~2. Currently on a leukotriene inhibitor or used within the past 6 months~3. Prior chest wall radiation~4. Pregnant or breastfeeding~5. Hepatic impairment as defined by:~   • AST(SGOT) \> 2.5X institutional ULN and ALT(SGPT) \> 2.5X institutional ULN~6. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Zafirlukast (Type: EXPERIMENTAL): Zafirlukast
- Standard of Care (no intervention) (Type: OTHER): Standard of Care (no intervention)

Based on this trial design, predict the completion outcome and termination type (if applicable).